10,012
Total Claims
$2.0M
Drug Cost
1,238
Beneficiaries
$1,625
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+7%
Cost per patient vs peers
$1,625 vs $1,524 avg
+55%
Brand preference vs peers
21.1% vs 13.7% avg
Brand vs Generic
79% generic
Brand: 2,116 claims · $1.8M
Generic: 7,896 claims · $199K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 849 | $860K |
| Sacubitril/Valsartan | 311 | $340K |
| Rivaroxaban | 167 | $163K |
| Evolocumab | 203 | $149K |
| Dapagliflozin Propanediol | 109 | $122K |
| Alirocumab | 45 | $50K |
| Dronedarone Hcl | 21 | $21K |
| Evolocumab | 31 | $19K |
| Bempedoic Acid | 16 | $15K |
| Ezetimibe | 350 | $11K |
| Torsemide | 299 | $9,458 |
| Metoprolol Succinate | 568 | $9,245 |
| Ranolazine | 74 | $8,959 |
| Acebutolol Hcl | 135 | $8,584 |
| Telmisartan | 188 | $8,102 |
Prescribing Profile
64
Unique Drugs
$1.5M
Patient Profile
75
Avg Age
49%
Female
1.60
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data